# When should lockdown be implemented? Devising costeffective strategies for managing epidemics amid vaccine uncertainty

Nathan J. Doyle<sup>1,2\*</sup>, Fergus Cumming<sup>3</sup>, Robin N. Thompson<sup>4</sup>, Michael J. Tildesley<sup>2</sup>

1 EPSRC Centre for Doctoral Training in Mathematics for Real-World Systems, Mathematics Institute, University of Warwick, Coventry, United Kingdom 2 The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, Mathematics Institute and School of Life Sciences, University of Warwick, Coventry, United Kingdom. 3 Foreign, Commonwealth and Development Office, London, United Kingdom 4 Mathematical Institute, University of Oxford, Oxford, United Kingdom. 10

Corresponding Author. Email: nathan.dovle@warwick.ac.uk;

### Abstract

During an infectious disease outbreak, public health policy makers are tasked with strategically 13 implementing control interventions whilst balancing competing objectives. To provide a quantitative 14 framework that can be used to guide these decisions, it is helpful to devise a clear and specific 15 objective function that can be evaluated to determine the optimal outbreak response. In this study, 16 we have developed a mathematical modelling framework representing outbreaks of a novel emerging 17 pathogen for which non-pharmaceutical interventions (NPIs) are imposed or removed based on 18 thresholds for hospital occupancy. These thresholds are set at different levels to define four unique 19 control strategies. We illustrate that the optimal intervention strategy is contingent on the choice of 20 objective function. Specifically, the optimal strategy depends on the extent to which policy makers 21 prioritise reducing health costs due to infection over the costs associated with control interventions. 22 Motivated by the scenario early in the COVID-19 pandemic, we incorporate the development of a 23 vaccine into our modelling framework and demonstrate that a policy maker's belief about when a 24 vaccine will become available in future, and its eventual coverage (and/or effectiveness), affects the 25 optimal control strategy to adopt early in the outbreak. Furthermore, we show how uncertainty in 26 these quantities can be accounted for when deciding which interventions to introduce. This research 27 highlights the benefits of policy makers being explicit about the precise objectives of introducing 28 interventions. 29

12

11

2

3

4

5

6

7

30

### 1 Introduction

The COVID-19 pandemic has highlighted the importance of mathematical and statistical models for 31 informing and guiding public health policy decisions [1–3]. For example, infectious disease models 32 can be used to assess the effects of non-pharmaceutical interventions (NPIs) [4] or to test different 33 vaccination strategies [5] in real-time during an epidemic, informing policy makers about effective 34 control strategies to implement moving forwards. Policy makers are required to consider a range 35 of costs in order to determine the optimal policy for outbreak management. The overall cost of an 36 epidemic includes both the direct effects of disease (as quantified by public health metrics such as 37 the total number of infections, hospitalisations and deaths) and the economic costs associated with 38 the maintenance of control measures designed to suppress the epidemic. It is usually desirable to 39 take both measures into account when deciding upon the control strategy to implement, but the 40 degree to which multiple objectives relating to disease burden and economic factors are weighed in 41 the final decision is often unclear. In the early stages of the COVID-19 pandemic, for example, there 42 was extensive discussion regarding the contrast in the timing and principles of control strategies 43 adopted in different countries [6]. Certain governments such as China and Australia favoured a 44 "zero-COVID" suppression strategy as opposed to less stringent policies adopted by countries such 45 as Sweden. In the absence of a vaccine, countries only had NPIs at their disposal to mitigate disease 46 spread. These intensive interventions were effective at controlling the epidemic [7], but resulted in 47 negative economic and social consequences [8, 9]. On the other hand, less stringent approaches 48 reduce the non-disease harms, but result in more individuals being exposed to infection and hence 49 more severe disease outcomes in the short term, as observed in Sweden and the United Kingdom 50 where less intense restrictions were adopted to curb COVID-19 in summer 2020 [10]. For models to 51 be used to identify the optimal policy, it is necessary to define the objectives of control explicitly 52 [11]. If policy objectives are clearly stated, epidemiological modellers can construct an objective 53 function that can be quantified and used to guide decision making. 54

Objective functions have been constructed previously in epidemiological studies in which optimal 55 control theory is applied to identify optimal disease management strategies [12–17]. Factors typically 56 considered in the cost function include a measure of disease burden and time-dependent control 57 variables, balanced by weighting coefficients. The disease burden contribution can be based on 58 quantities such as the number of infected individuals [14] or can instead be based on the impact 59 on healthcare resources (through e.g., the number of hospitalised individuals). The cost of control 60 can include treatment and vaccination effort [16], which is often included in a nonlinear fashion to 61 reflect, for example, the disproportionate costs at heightened control efforts [17]. Once an objective 62 function has been formulated, different control strategies can be tested. In some studies, a limited 63 range of different interventions are tested, and in others it is possible to identify the optimal strategy 64 from a substantial range of possibilities. 65

In a previous study, Probert et al. [11] discussed the need for an objective function to be 66

constructed for evaluating intervention strategies in the context of foot-and-mouth disease (FMD). 67 Strategies for FMD control can incorporate the targeted culling of livestock, including those that are 68 not yet infected, which leads to both the death of animal hosts and substantial direct economic costs 69 to farmers. Those authors demonstrated that the optimal control action is highly dependent upon 70 both the objectives of disease management and the epidemiological model used to guide decision 71 making. In that study, different strategies are ranked comparatively rather than highlighting the 72 best performing strategy alone. This is important as it can inform policy makers about robust 73 control strategies that perform relatively well across a range of modelling assumptions and objective 74 functions. If the cost function is well-defined, policy makers may consider the risk of a catastrophic 75 cost occurring (i.e., a reasonable worst case scenario), which can be explored if the underlying 76 simulation model incorporates uncertainty. We build on this previous work by considering how 77 different objective functions lead to different optimal interventions in the context of a novel disease of 78 humans, accounting for features of outbreaks that are particularly pertinent to outbreaks in human 79 populations (e.g. the rapid development of a vaccine, as was undertaken during the COVID-19 80 pandemic). 81

A key challenge for epidemiological modellers when designing models for use to guide interven-82 tions is to account for uncertainties about outbreak dynamics and the effects of interventions, par-83 ticularly at the early stages of the outbreak. Such uncertainties should be reflected when evaluating 84 control measures using any objective function. Examples of sources of uncertainty which may affect 85 the projected impacts of the outbreak include uncertainty in the parameters underlying pathogen 86 transmission [18], the effectiveness of a potential vaccine and/or other control measures [19] and the 87 economic impacts of control [20]. A particular source of uncertainty which likely affected decision 88 making at the beginning of the COVID-19 pandemic was related to future vaccination prospects. 89 COVID-19 vaccines were developed rapidly as vaccination became a global research priority early in 90 the pandemic [21]. However, the time that it would take for effective vaccines to be developed and 91 approved, as well as their eventual uptake, were unknown in the early months of the pandemic [22]. 92 This likely affected early decision making regarding the implementation of NPIs, as the swift arrival 93 of a highly effective vaccine would allow policy makers to maintain interventions with assurance of 94 an imminent path to higher levels of (vaccine-induced) immunity in the population. Thus, a key 95 feature of our current study is an investigation into how the optimal control strategy early in an 96 outbreak changes based on uncertainty about whether or when a vaccine will be developed, as well 97 as its eventual effectiveness and coverage. 98

In this paper, we present an age-structured mathematical model for the spread of a novel emerging pathogen. The model explicitly tracks the number of individuals in hospital as a result of severe infection during the epidemic, which is used as a trigger to switch between three levels of populationwide infection control. We consider four different possible control strategies, each of which is defined by the precise trigger values at which interventions are changed. The performance of each control strategy is evaluated using model projections and an objective function that takes into account 104

disease burden, the cost of control and the risk of hospital capacity being exceeded at any stage during the epidemic. Crucially, we demonstrate how the optimal control strategy changes according to the relative weighting of disease burden and control stringency contributions in the objective function, as well as the time horizon that is considered.

Our goal is to develop a general epidemiological modelling framework that can be extended 109 and used to guide interventions during future outbreaks of a range of pathogens, rather than to 110 provide a detailed model that represents specific features of the COVID-19 pandemic. However, 111 to demonstrate how the model can be used in specific scenarios, we consider a situation in which 112 NPIs are being implemented but a vaccine may become available in future (as was the case early in 113 the COVID-19 pandemic). We show how uncertainty in the time at which the vaccine will become 114 available can be accounted for when determining the current optimal control strategy. We show that 115 the optimal strategy can be different when accounting for the possibility of vaccine development 116 compared to the vaccine-absent scenario. Finally, we consider different ways in which objective 117 functions can be used to identify optimal control measures - including minimising the expected 118 value of the objective function or minimising different quantiles of the objective function. The 119 latter approach allows policy makers to choose, for example, to introduce control to limit impacts 120 of the "worst case" scenario. Taken together, this work provides a framework that can be used to 121 test different control interventions during future outbreaks of a range of pathogens. 122

## 2 Methods

#### 2.1 Epidemiological model

We consider a general deterministic model of pathogen transmission in a closed population, com-125 prising a system of ordinary differential equations (see supplementary material). It is based upon 126 the model initially developed by Keeling et al. [23] to simulate COVID-19 dynamics within the 127 United Kingdom, although as noted above explicitly modelling COVID-19 is not the focus of our 128 study. The population comprises of individuals subdivided into three demographic cohorts of ages 129  $G = \{0 - 19, 20 - 64, 65 +\}$  to reflect variability in disease severity with age; namely, the age-130 dependent probabilities of developing symptomatic infection  $(d_a)$  and the probabilities of hospi-131 talisation given symptomatic infection  $(h_a)$ . Transmission is also dependent on the ages of the 132 potential infectors and infectees, based upon mixing matrices derived from social contact patterns 133 in the United Kingdom [24]. Transmission rates are scaled so that the basic reproduction number 134 (calculated using the Next Generation Matrix approach [25]) takes the value  $R_0 = 3$ . 135

The model includes four infectious classes. Asymptomatic infection is differentiated from symptomatic infection, which is further subdivided by severity (including whether the individual is hospitalised). The prevalence of individuals in the hospitalised compartment is used as a trigger to introduce or relax control measures. All four infectious classes contribute towards transmission, al-139

123

though we assume that asymptomatic individuals are less infectious (e.g., due to a lower viral load) 140 and hospitalised individuals have significantly fewer contacts due to ward isolation (while allowing 141 for the possibility of nosocomial transmission [26]). The waning of immunity is possible sometime 142 after an individual recovers from infection. The time spent in the recovered class is assumed to 143 follow an Erlang distribution, so that immunity is unlikely to wane immediately (as opposed to 144 under the more standard assumption of an exponential distribution). The mean of this distribution 145 is 800 days and the standard deviation is 462 days. This broad distribution was chosen to allow 146 reinfections to occur over the timescale of the simulated outbreaks, but to ensure that infection 147 induces immunity in most infected individuals in the initial stages of the outbreak. We also take 148 deaths in hospital settings into consideration. 149

Gamma or Erlang distributions have been found to represent epidemiological periods more 150 accurately than exponential distributions [27]. The Erlang distributed period of waning immunity 151 is implemented using the method of stages [27], which is also used to obtain Erlang distributed latent 152 and infectious periods in our model. A schematic illustrating the model's compartmental structure 153 is shown in Figure 1. A detailed description of the model is provided in the supplementary material. 154

155

170

#### 2.2 Control

Policy makers are assumed to manage the spread of the pathogen by switching between three control 156 states for population-wide physical distancing measures. The policy makers can impose No Control 157 (state 0) on the system or implement control measures which vary between Intermediate Control 158 (state 1) or Lockdown (state 2). Control is associated with a fixed reduction in all transmission 159 rates  $\beta_{ij}$  (40% and 70% reductions in transmission respectively for the Intermediate Control and 160 Lockdown states in comparison to the No Control state). Switching between control states is deter-161 mined by relaxation or reintroduction of measures based upon the total active number of individuals 162 in the hospitalised compartments,  $I^{H}(t) = \sum_{a \in G} I^{H}_{a}(t)$ , in the simulation. We incorporate differ-163 ent control policies by defining four control strategies with distinct relaxation and reintroduction 164 thresholds. We note that the thresholds for introducing and relaxing interventions are not neces-165 sarily identical. For example, policy makers may relax measures from lockdown to intermediate 166 control at a lower threshold number of hospitalisations than are required to move from intermediate 167 control to lockdown, reflecting the fact that measures are only likely to be relaxed when there is 168 substantial evidence that the outbreak is being controlled effectively. 169

The principles of each control strategy that we consider are summarised below.

• S1 (Cautious easing): This strategy sets low thresholds for relaxing control with a high threshold for entering full lockdown. This strategy is conservative in that it aims to enforce moderate control throughout the epidemic but simultaneously seeks to limit the number of phases and duration spent in lockdown.



Figure 1: Epidemiological model structure. Schematic illustrating the structure of the model that governs the disease dynamics. Susceptible individuals  $(S_a)$  can acquire infection from any of the four infectious classes (asymptomatic  $(I_{a,m}^A)$ , symptomatic without requiring hospital treatment  $(I_{a,m}^S)$ , symptomatic and eventually requiring hospital treatment  $(I_{a,m}^P)$  and hospitalised with severe disease  $(I_a^H)$ ), highlighted by the grey box. Immediately following infection, individuals temporarily occupy an exposed class  $(E_{a,m})$  where they spend the latent period, before progressing to the infectious classes according to age-dependent severity parameters  $d_a$  and  $h_a$ . At the end of the infectious period, individuals who recover remain in the  $R_{a,m}$  class until they undergo natural waning immunity and return to the susceptible class. Disease-induced mortality occurs in hospital settings at age-dependent probability  $\mu_a$ , and deceased individuals are removed from the model. Where relevant, subscripts distinguish between demographic cohorts  $a \in G = \{0-19, 20-64, 65+\}$  and Erlang-stage classification  $m \in \{1, 2, 3\}$ .

- S2 (Suppression): This strategy aims to maintain a low prevalence, using very low thresholds for relaxation and introduction, at the cost of frequent jumps between Lockdown and Intermediate Control. This is an extreme case which prolongs the epidemic but may be beneficial when the arrival of an effective vaccine is likely.
- S3 (Slow control): Similarly to the Cautious easing strategy, this strategy enforces low 179 thresholds to return to No Control and a high threshold to enter Lockdown. In contrast, the 180 threshold to relax from Lockdown to the Intermediate Control state is high, in the hope that 181 relaxing to the Intermediate Control state is sufficient to prevent disease resurgence. 182
- S4 (Rapid control): This strategy is characterised by a high switching threshold to return to No Control and a narrow gap between all thresholds. It allows for swift relaxation from Lockdown to No Control, keeping the duration of continuous intervention periods low. Prevalence of infections and hospitalisations can be higher than other strategies, but measures can be reintroduced swiftly to avoid exceeding healthcare capacity.

The principles of each strategy are encapsulated by four switching thresholds – two each for 188 relaxation and reintroduction of control measures. We use  $T_{ij}$  to depict the switching threshold 189 (in the number of currently hospitalised individuals) for moving from control state i to control 190 state j. Table 1 lists the switching thresholds for the four control strategies considered. Decisions 191 regarding the switching of control measures are discrete and occur at the beginning of each day in 192 the simulation. The new control state is implemented after a three-day delay following the switching 193 threshold being triggered to account for logistics and the change in behaviour of the population in 194 response to new control measures. Control states must last at least three weeks before relaxation 195 can take place and at least two weeks before reintroduction can be imposed, as in reality policy 196 makers are unable to change policy on a daily basis. This is inclusive of the aforementioned three-197 day implementation delay. If the outbreak is rapidly growing and the  $T_{12}$  threshold is triggered 198 during the No Control state, policy makers move directly to Lockdown. However, it is not possible 199 to skip the Intermediate Control state for total relaxation; we assume that Intermediate Control 200 is a necessary precursor to returning to No Control. Policy makers will also never choose to relax 201 measures if hospital occupancy is growing at the time that the relevant relaxation threshold is 202 triggered. 203

ID	Name	$T_{01}$	$T_{12}$	$T_{21}$	$T_{10}$
S1	Cautious easing	100	500	150	50
S2	Suppression	100	200	150	50
S3	Slow control	200	500	400	100
S4	Rapid control	300	450	350	200

Table 1: Control strategy thresholds for hospital occupancy. Thresholds  $T_{ij}$  for the number of active hospitalisations  $I^H(t)$  required to switch control state under each of the four control strategies.

#### 2.3 Objective Function

We define H(t) and u(t) to be the number of new hospital admissions and the level of control 205 (relative reduction in transmission), respectively, over the previous day [t-1,t] in the epidemic, for 206  $t \in \{t_0 + 1, \ldots, t_f\}$ . The objective function J that we use in this study to evaluate epidemic costs 207 given a control strategy takes the following form: 208

$$J(H, u, w) = \sum_{t=t_0+1}^{t_f} \left( w \frac{H(t)}{\phi_b} + (1-w) \frac{(u(t))^2}{\phi_s} \right) + \exp\left( w_H(\max[I^H(t)] - H_c) \right).$$
(1)

The cost function contains three major components each associated with weights  $(w, w_H)$ . The 209 first component measures severe disease outcomes based on total hospital admissions. The second 210

component measures the cost of maintaining control measures which may be associated with a 211 continuous economic cost. We assume this to scale non-linearly with greater levels of stringency, so 212 that Lockdown is disproportionately costly. The constants  $\phi_b = 30,100$  and  $\phi_s = 252.5$  normalise 213 both cost contributions against the highest costs observed across all scenarios explored in this work, 214 so that each cost contribution varies on a similar scale. The weighting  $w \in [0,1]$  represents the 215 extent to which the policy maker trades-off the competing objectives (increasing w places a larger 216 emphasis on reducing the direct public health costs as opposed to the costs of interventions). The 217 third (exponential) component acts to heavily penalise strategies under which a specified capacity 218 on peak hospitalised individuals,  $H_c$ , is exceeded. This component gives a negligible contribution to 219 strategies which maintain a below-capacity level of hospitalised individuals, but a rapidly increasing 220 contribution once hospital capacity is exceeded (See Figure S3 for a demonstration of this qualitative 221 behaviour). In this study, this weighting is fixed at  $w_H = 2$ . No discounting of costs is applied 222 in the objective function in our baseline analyses due to the short simulation timescales, but the 223 results were robust to discounting at a rate of 3.5% per annum (Figure S18). 224

This objective function can be used to evaluate a standalone cost for a given scenario or yield <sup>225</sup> a distribution of costs when uncertainty is incorporated. It then becomes important to consider <sup>226</sup> the summary statistic used to identify the optimal strategy which may reflect a level of acceptable <sup>227</sup> risk. A robust strategy could require, for example, a low risk of a reasonable worst-case scenario in <sup>228</sup> addition to a low expected cost. Thus, different statistics arising from the distribution of strategy <sup>229</sup> costs were calculated to explore how the effectiveness of the four control strategies are affected by <sup>230</sup> uncertainty. <sup>231</sup>

#### 2.4 Vaccination

In the midst of a global pandemic, vaccination rates can be nonlinear due to logistical bottlenecks <sup>233</sup> and global inequalities [28]. Sasanami *et al.* [29] previously used a logistic function to model <sup>234</sup> COVID-19 vaccine coverage in Japan. In a similar vein, in our work the number of cumulative <sup>235</sup> vaccinations of age cohort  $a \in G$  at a time t days into the simulation – after the specified arrival <sup>236</sup> date T of a vaccine – is calculated using the logistic function, <sup>237</sup>

$$V_a(t) = \frac{\eta N_a}{1 + \exp(-\kappa (t - (T + t_c)))}.$$
(2)

The parameter  $\eta \in [0, 1]$  encapsulates the efficacy and eventual coverage of the vaccine. Given <sup>238</sup> the nature of our model, we are not explicitly considering vaccine efficacy and vaccine coverage <sup>239</sup> independently and therefore  $\eta = 0.5$  can be interpreted as either a vaccine with 50% eventual <sup>240</sup> coverage with 100% efficacy against infection, or a vaccine with a higher coverage and lower efficacy <sup>241</sup> against infection (resulting in an overall 50% reduction in susceptibility). Henceforth, we refer to  $\eta$  <sup>242</sup> as the eventual coverage of the vaccine. Adjusting the eventual coverage  $\eta$  can reflect vaccination <sup>243</sup>

campaigns with varying success. For fixed  $\eta$ , the remaining parameters  $\kappa$  and  $t_c$  control the speed 244 of increase of the vaccine rollout and the duration required (measured from deployment date T) to 245 obtain 50% of the final coverage, respectively. 246

Vaccination follows an age-staggered protocol by beginning with the 65+ demographic on de-247 ployment date T, before commencement of the 20-64 and 0-19 age groups after a delay of 248  $t_c/2$  and  $t_c$  days, respectively. Vaccination is assumed to target individuals in the susceptible and 249 recovered classes. Figure S4 demonstrates the cumulative vaccination uptake using the logistic 250 function (2) for an example simulation, using an arrival date of T = 360 days and parameters 251  $\eta = 0.9, \kappa = 0.05, t_c = 100$ . The parameters controlling the shape of the logistic function (namely, 252  $\kappa$  and  $t_c$ ) are fixed and the uncertainty in control strategy cost is generated by varying the arrival 253 date T and coverage  $\eta$ . 254

We incorporate uncertainty in the vaccine arrival time and coverage by selecting a specified 255 arrival date T and parameter  $\eta$  from discrete probability distributions, to limit the number of 256 required model simulations. We allow T to take discrete values between 60 and 1,080 days, in 257 increments of 60 days. Similarly, we allow  $\eta$  to take discrete values between 0 and 1, in increments 258 of 0.05. Four discrete probability distributions are generated to reflect distinct levels of optimism 259 regarding the timing and eventual coverage of the future vaccine. Visualisation and details regarding 260 the generation of these distributions are provided in the supplementary material. The principle 261 behind each distribution considered is summarised in the list below. 262

- D1 (Radical): Timeliness is prioritised over maximising efficacy in order to enable vaccination rollout as early as possible. Characterised by  $\mathbb{E}[T] = 420$  days,  $\mathbb{E}[\eta] = 0.25$ .
- D2 (Optimistic): The global focus on vaccine development has enabled a highly effective 265 vaccine to be deployed promptly. Characterised by  $\mathbb{E}[T] = 420$  days,  $\mathbb{E}[\eta] = 0.75$ . 266
- D3 (Pessimistic): Global factors render the vaccine significantly less timely and effective in comparison to those developed for COVID-19. Characterised by E[T] = 720 days, E[η] = 0.25.
- D4 (Conservative): A lengthier timeline for vaccine research and development leads to a higher quality vaccine. Characterised by  $\mathbb{E}[T] = 720$  days,  $\mathbb{E}[\eta] = 0.75$ . 270

Uncertainty leads to a cost distribution for each control strategy conditional on the joint probability distribution for the timing and eventual coverage of the vaccine. Denoting the set of possible combinations of vaccine arrival times and coverage by  $\Psi$ , the expected cost of a control strategy  $\mathbb{E}[J]$  is conditional on all plausible outcomes of T and  $\eta$ , 274

$$\mathbb{E}[J] = \sum_{(T,\eta)\in\Psi} \mathbb{E}[J|T,\eta] \mathbb{P}(T,\eta), \qquad (3)$$

where  $\mathbb{P}(T,\eta)$  is the probability mass function of the vaccine joint probability distribution. For a distribution of cost, we rank the control strategies based upon a number of criteria: 276

- 1. Minimise the expected (mean) cost,  $\mathbb{E}[J|$ Strategy].
- 2. Minimise the cost of the "most likely outcome" (corresponding to the mode of the  $(T, \eta)$  joint distribution, disregarding any other potential outcomes). 279
- 3. Minimise the 95th percentile cost (the cost  $J_c$  such that  $\mathbb{P}[J > J_c | \text{Strategy}] \approx 0.05$ ).
- 4. Maximise the probability of having the lowest cost,  $\sum_{(T,\eta)\in\Psi^S} \mathbb{P}(T,\eta)$ , where  $\Psi^S \subset \Psi$  is the set of outcomes in which strategy S is optimal (out of the four control strategies considered). 282

Some criteria focus upon minimising the objective function by averaging over all scenarios or 283 considering scenarios that are most likely to happen; for example, minimising the expected cost 284  $\mathbb{E}[J|$ Strategy] or the cost for the mode of the underlying vaccine distribution. Other criteria can be 285 viewed as a measure of strategy robustness, such as the 95th percentile cost which a policy maker 286 may perceive to reflect a "reasonable worst-case scenario". Such situations are particularly important to consider when there is high uncertainty regarding the future progression of the outbreak, or 288 when extreme scenarios can be particularly detrimental. 289

### 3 Results

#### 3.1 Model simulations

First, we explored the effects of the four control strategies considered on outbreak dynamics. Simulations were performed by numerically solving the differential equation system (see supplementary material), checking each day whether a switching threshold  $T_{ij}$  is triggered and implementing policy decisions accordingly. Each simulation was preceded by a 30-day preliminary simulation without any control, since in reality interventions are not implemented instantaneously when a pathogen first arrives in the population.

Without vaccination, each control strategy considered led to different outbreak dynamics (Figure 298 2). Hospital levels in the Cautious easing strategy rose to a high first peak as a consequence of the 299 high  $T_{12}$  threshold. This strategy had the fewest waves of infection across the time frame used and 300 was also the only control strategy in which Lockdown was only implemented once. In contrast, under 301 the Suppression control strategy, the narrow gap between thresholds leads to frequent switching 302 between Intermediate Control and Lockdown without a break in measures to return to No Control. 303 However, high stringency was rewarded by generally low prevalence and overall disease burden 304 was lowest when measured throughout the epidemic. For the Slow control strategy, there were 305 two short successive periods of Lockdown in response to high levels of infection. This resulted in 306 the effective reproduction number falling below one after the second lockdown and low hospital 307

290

277



Figure 2: Hospitalisation dynamics in the absence of vaccination. Number of active hospitalised individuals across all age cohorts  $I^{H}(t)$  for each control strategy, in the scenario with no vaccination. Strategies are labelled as (a) S1 (Cautious Easing), (b) S2 (Suppression), (c) S3 (Slow Control) and (d) S4 (Rapid Control). Shaded are the periods spent in (red) Lockdown, (yellow) Intermediate Control and (white) No Control. The switching thresholds  $T_{ij}$  are marked with horizontal dashed lines.

occupancy was maintained before a brief return to No Control and smaller waves of infection. <sup>308</sup> Finally, the narrow gaps between switching thresholds for the Rapid control strategy allowed the <sup>309</sup> epidemic to be managed at a moderate but sufficiently low level of infection such that hospital <sup>310</sup> capacity was never overwhelmed. This required regular switching between controls – this simulation <sup>311</sup> moved through the largest number of phases of all strategies with four phases of Lockdown in total. <sup>312</sup> Additionally, the high  $T_{10}$  threshold meant that this strategy allowed the longest and most frequent <sup>313</sup> periods of No Control. <sup>314</sup>

Outbreak dynamics with vaccination are shown in Figure S5 for initial vaccine deployment <sup>315</sup> time T = 360 and eventual coverage (or effectiveness)  $\eta = 0.9$ . Since the vaccination coverage was <sup>316</sup> sufficiently above the critical level  $1-1/R_0$  required to eradicate infection [30], and waning immunity <sup>317</sup> was assumed to occur slowly, the vaccine presented itself as a rapid pathway out of the epidemic for <sup>318</sup> this scenario, with the pathogen approaching elimination after the onset of vaccination. However, <sup>319</sup> there remained the possibility for smaller waves of infection, and corresponding reintroduction of <sup>320</sup> NPIs, while vaccination was taking place. <sup>321</sup>

The ranking of control strategies using the objective function (1) depends upon the policy 322 maker's choice about the relative importance of reducing the costs due to disease or the costs of 323 stringent public health measures. In our model, this choice determines the value of the parameter 324



Figure 3: Strategy rankings. Ranking of control strategies with respect to weighting w for choice of hospital capacity  $(H_c)$  and time horizon  $(t_f, \text{ in days})$ : (a)  $H_c = 1,250$ ,  $t_f = 360$ , (b)  $H_c = 1,250$ ,  $t_f = 720$ , (c)  $H_c = 1,250$ ,  $t_f = 1,080$  and (d)  $H_c = 1,000$ ,  $t_f = 1,080$ . The figure shows the scenario of no vaccination (left) contrasted with a vaccination scenario for  $\eta = 0.9$  and T = 360 days (right).

w. The ranking of the four strategies is shown for a range of values of w, both in the absence of 325 and with vaccination, in Figure 3. When a short time horizon  $t_f$  is considered, the optimal strategy 326 was either Slow Control or Suppression, depending on the value of w. Over longer time horizons, 327 each of the four strategies were optimal in different scenarios, again depending on the precise value 328 of w but also the level of hospital capacity. When hospital capacity  $H_c$  is lowered from 1,250 to 329 1,000 individuals, the Cautious Easing and Slow Control strategies are suboptimal as their first 330 wave peaks (1,052 individuals) would overwhelm capacity and are thus infeasible strategies (Figure 331 3d). To allow for the consideration of all four strategies henceforth,  $H_c$  will remain fixed at 1,250 332 individuals (1.25 beds per 1,000 population). The variance in strategy rankings across Figure 3 333 demonstrates that the objective of the policy maker is crucial in determining the optimal control 334 strategy. 335

#### 3.2 Incorporating vaccination uncertainty

We then simulated the model while varying the vaccine arrival time and coverage parameters  $(T, \eta) \in$ 337  $\Psi$  to represent plausible vaccination scenarios. The time horizon used in each model simulation was 338 1,080 days (approximately 3 years). Surface plots depicting the overall cost of the outbreak under 339 each control strategy as a function of w and vaccine arrival time T are shown in Figure 4. Different 340 rows in Figure 4 reflect different levels of eventual vaccine coverage,  $\eta$ . Analogous surface plots 341 of cost by control strategy are also provided in which the vaccine coverage parameter  $\eta$  is varied 342 continuously for specific vaccine arrival times T = 360 (Figure S6a), T = 630 (Figure S6b) and 343 T = 900 (Figure S6c). Notably, the most stringent strategy (Suppression) is most likely to be 344 optimal when the policy maker prioritises lowering disease costs (i.e. a high value of w) and when 345 the vaccine is developed quickly and high vaccination coverage is achieved (see, for example, low 346 values of T in Figure 4c). In contrast, the Slow control and Rapid control strategies are optimal 347 for lower values of w, with the optimal strategy in that case depending on the time at which the 348 vaccine will be developed and the eventual vaccination coverage. 349

336

The probability distributions which characterise vaccine-related uncertainty (detailed in Figure 350 S2) were used to generate a distribution of possible outbreak costs under the four control strategies, 351 assuming that  $H_c = 1,250$  individuals. These costs are shown in Figure 5, centre. Predictably, 352 a shorter waiting time T for vaccine development and a greater eventual coverage  $\eta$  were associ-353 ated with the smallest expected cost; both of these aspects are necessary to achieve a significant 354 reduction in cost in comparison to the pessimistic distribution (Figure 5c). The expected cost of 355 the Suppression strategy decreased with w and increased for the remaining strategies. The Sup-356 pression strategy generally had the widest credible interval for cost. While this strategy certainly 357 benefits from a prompt vaccine arrival, delays to vaccine deployment resulted in overwhelming costs 358 to maintain control with minimal reduction in hospitalisation as alternative strategies returned to 359 low levels without control measures. 360

For each distribution characterising uncertainty in when a vaccine will be developed and its 361 eventual coverage, we calculated the probability that each control strategy leads to the lowest cost 362 (Figure 5, right) or the highest cost (Figure S7). These probabilities were calculated by first ranking 363 the control strategies separately for each combination of  $(T, \eta)$ . Then, the proportion of values 364 (weighted by the relative likelihood of each  $(T, \eta)$  combination) in which each strategy leads to the 365 lower (or highest) cost was computed. Conveying strategy performances in terms of probabilities can 366 assist the decision making process, as policy makers may be inclined to adopt strategies with a high 367 likelihood of being optimal or a low likelihood of performing poorly. Regardless of the underlying 368 vaccine distribution, the Suppression strategy had a high probability of being optimal for larger 369 w, but the performance of the Slow control strategy for low w depended upon the probability 370 distribution characterising future vaccine availability and coverage (i.e., this strategy performed 371 well when the vaccine was expected to be developed quickly and when it was expected to have high 372



Figure 4: Outbreak costs under different control strategies for different assumptions about the timing of vaccine development and the eventual vaccination coverage. Surface plots of cost (evaluated by the objective function (1) for different values of the weighting w and the timing of the arrival of the vaccine (left). The z-axis has the lowest cost at the top, allowing the optimal strategy (corresponding to the lowest cost) to be seen more clearly. Results were generated separately for vaccine coverage (a)  $\eta = 0.1$ , (b)  $\eta = 0.5$  and (c)  $\eta = 0.9$ . The control strategies are coloured as follows: yellow (Cautious easing), green (Suppression), purple (Slow control) and blue (Rapid control).

coverage). Since the Suppression and Rapid control strategies typically resulted in the largest level  $_{373}$  of control or hospitalisations respectively, they also maximised the probability of having the highest  $_{374}$  cost irrespective of the vaccine probability distribution when the weighting w was unfavourable (see  $_{375}$  Figure S7).  $_{376}$ 

We also evaluated the control strategies based upon different ranking criteria (see Methods). For  $_{377}$  the same weight w, the optimal choice was dependent upon the ranking criteria used (Figure S8). For  $_{378}$  the Optimistic joint probability distribution (Figure 5b), the Suppression strategy was favourable  $_{379}$ 



Figure 5: Effect of uncertainty in when a future vaccine will be developed and its likely coverage on the outbreak cost and the optimal control strategy. The underlying distribution of vaccine outcomes (left), resulting in cost distributions for the control strategies which varied according to weight w (center), in addition to the probability each strategy had the lowest cost across outcomes (right). The joint distributions (rows) covered a range of optimistic and pessimistic scenarios regarding the effectiveness of the vaccination campaign; (a) D1 (Radical) distribution, (b) D2 (Optimistic) distribution, (c) D3 (Pessimistic) distribution, (d) D4 (Conservative) distribution. The expected costs,  $\mathbb{E}[J]$ , are marked by the scatter points, and the shaded regions indicate the 2.5th and 97.5th cost percentile.

for intermediate w when the goal is to minimise the expected (mean) cost, most likely cost (mode of the vaccine distribution) or maximise the probability of having the lowest cost. However, it did not fare as well if policy makers instead choose to minimise the 95th percentile cost. Likewise, the performance of the Slow control strategy worsened if we consider the 95th percentile cost in the case of lower w. This again highlights the need for policy makers to consider their objectives carefully when determining the control strategy to implement. 385

### 4 Discussion

In this study, we have demonstrated that optimal interventions in the early stages of infectious 387 disease epidemics depend on the precise objectives of the policy maker. The optimal control strategy 388 to introduce depends on the extent to which the policy maker chooses to prioritise lowering negative 389 disease-related costs (e.g., numbers of hospitalisations) or limiting the costs of control (e.g., the 390 economic and social costs associated with stringent measures) - see Figure 3. We also showed how 391 key uncertainties can be accounted for in the decision making process - for example, uncertainty in 392 the time required for a vaccine to be developed and the level of vaccine uptake in the host population 393 (Figure 5). 394

386

Of the strategies that we considered, we found that the stringent Suppression strategy was 395 most likely to be optimal if a vaccine was expected to be developed quickly and a high vaccination 396 coverage could be achieved (Figure 4c). In that scenario, intensive control measures could limit 397 the negative effects of disease until the vaccine became available. In contrast, less stringent NPIs 398 were more likely to be beneficial if vaccine development was expected to take a long time and/or 300 vaccination uptake was expected to be low (Figure 4a). In addition, we found that the optimal 400 strategy can differ according to whether a policy maker prefers to minimise the expected outbreak 401 cost or the risk of a "reasonable worst case" scenario occurring (Figure S8). 402

The work that we have presented here builds on a substantial body of previous research. The 403 objective function used to evaluate control strategies in this study was informed by cost functions 404 that have previously been used when optimal control theory approaches have been applied in the 405 context of infectious disease epidemiology [12-16]. The nature of these functions allow for the dual 406 consideration of health-associated costs in addition to control-associated costs when deciding upon 407 an optimal strategy. Previous research articles have investigated the impacts of vaccination in the 408 context of the COVID-19 pandemic using scenario modelling, including considering different vaccine 409 effectiveness and uptake levels [19], deployment strategies [5, 31] and assumptions surrounding the 410 health and economic benefits of vaccination [20]. Modelling of this type is increasingly used in real-411 time during infectious disease outbreaks to guide policy decisions. Our study extends this previous 412 work by considering how uncertainty relating to future vaccination (i.e., the time required to develop 413 the vaccine and its effectiveness or uptake) can be incorporated into methods for determining optimal 414 interventions in the initial stages of an infectious disease outbreak. 415

As with any mathematical modelling study, our research involved necessary simplifications. The <sup>416</sup> objective function used was relatively simple, allowing us to consider how disease-related costs could <sup>417</sup> be balanced against the costs of control in as straightforward a setting as possible. However, the <sup>418</sup> overall cost of an epidemic is not limited to the factors that we considered (i.e., hospitalisations <sup>419</sup> and the maintenance of control measures). Accurate assessment of the cost of an outbreak should <sup>420</sup> require other factors to be included and quantified, for example long-term health harms due to <sup>421</sup> stringent control measures being implemented for long periods. This can include mental health <sup>422</sup>

impacts [32] or complications arising from the cancellation of elective surgeries [33]. The true costs 423 incurred as a result of an epidemic can be extremely complex to measure and may continue to 424 accumulate beyond the lifetime of the epidemic. Previous work has investigated the economic cost 425 of implementing control by fitting polynomial functions describing GDP reduction as a function of 426 lockdown intensity and duration [34], or by modelling GDP reduction as a function of disease and 427 control induced unemployment [35]. Another potential future consideration is that the effectiveness 428 of different measures may change during an epidemic - for example, lockdown may be less effective 429 if it is introduced multiple times or maintained for a long period, since this would likely lead to a 430 reduction in public compliance with government guidelines. 431

In addition, we considered a limited range of control strategies in this study. All of these strate-432 gies were based on thresholds in the prevalence of hospitalised individuals. However, in principle 433 other triggers for changing NPIs could be considered, for example thresholds in numbers of infections 434 or deaths, or in estimated outbreak growth rates or reproduction numbers. Further investigation 435 into the impacts of different approaches for determining when control measures should be changed 436 is a key area for future work. Even if thresholds in the numbers of hospitalised individuals are 437 used to determine when to amend interventions, in principle the values of the thresholds could be 438 optimised considering all possible values (as opposed to the four strategies that we considered here), 439 at the cost of a huge range of different control strategies to explore. 440

To limit the dimensions of uncertainty, the vaccine in this study was only allowed to vary in its 441 deployment time T and eventual coverage  $\eta$ . Here we use the parameter  $\eta$  as a catalyst to capture 442 a wide array of different vaccine-induced dynamics which range from minimal effect to driving the 443 pathogen extinct. In reality, the efficacy of vaccines against infection, disease and hospitalisation 444 can be unknown prior to large-scale clinical trials and deployment. Increasing the complexity of 445 vaccination can be examined in future projects. Epidemiological parameters in the disease model 446 were fixed as the primary objective was to investigate vaccine-induced uncertainty, however at the 447 beginning of a novel outbreak there can be substantial uncertainty regarding pathogen transmis-448 sion and disease severity. Sensitivity analyses suggest that despite noticeable changes in epidemic 449 trajectories for the four control strategies as parameters are varied, their relative ranking in cost 450 contributions remains largely unchanging (see supplementary material). Scenario modelling is al-451 ways sensitive to parameterisation and this motivates the resolution of parameter uncertainty as 452 early as possible during infectious disease outbreaks. 453

Nonetheless, despite these simplifications, our approach enabled us to demonstrate clearly that <sup>454</sup> identification of the optimal control strategy relies upon the objectives of control being set out clearly <sup>455</sup> by policy makers. If these objectives are clearly stated, and if relevant costs can be quantified, then <sup>456</sup> epidemiological modelling can be used to assess the effectiveness of different strategies. Moreover, <sup>457</sup> in settings in which there are relevant uncertainties - for example, uncertainty in the precise costs <sup>458</sup> of different control strategies or uncertainty about when a new vaccine may be developed - then the <sup>459</sup> modelling framework that we have presented can be used to identify the optimal control strategy <sup>460</sup>

accounting for those uncertainties (i.e., based on the best available evidence). As we showed by including the potential for a vaccine to be developed, our modelling framework is easily extensible. We therefore hope that this research lays the foundation for policy makers to be able to assess the likely effectiveness of different control strategies during future outbreaks of a range of different pathogens.

## Author contributions

N.J.D. developed the software, performed the analyses, visualized the results and wrote the original draft.
 N.J.D., R.N.T. and M.J.T. developed the methods.
 R.N.T. and M.J.T. supervised the work.
 All authors conceptualized the study, reviewed and edited the manuscript, and approved the final version for publication.

## Competing interests

We declare that we have no competing interest.

### Data and code availability

All data generated or analysed during this study, including computing code for reproducing our 474 results, are available at: 475 https://github.com/ndoyle815/Epidemic-strategies-amid-vaccine-uncertainty. 476

## Funding

N.J.D. and M.J.T. were supported by the Engineering and Physical Sciences Research Council through the Mathematics of Systems II Centre for Doctoral Training at the University of Warwick (grant number EP/S022244/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 480

## References

- Eker, S. Validity and usefulness of COVID-19 models. Humanit. Soc. Sci. Commun. 7, 54 (2020).
- Brooks-Pollock, E., Danon, L., Jombart, T. & Pellis, L. Modelling that shaped the early COVID-19 pandemic response in the UK. *Phil. Trans. R. Soc. B* 376, 20210001 (2021).
- Thompson, R. Epidemiological models are important tools for guiding COVID-19 interventions. BMC Med. 18, 152 (2020).

482

# 466

471 472

473

- Ferguson, N. et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce 489 COVID-19 mortality and healthcare demand. *Technical Report* (Imperial College London, 490 2020).
- Moore, S., Hill, E., Dyson, L., Tildesley, M. & Keeling, M. Modelling optimal vaccination 492 strategy for SARS-CoV-2 in the UK. *PLoS Comput. Bio.* 17, 1–20 (2021).
- Pearce, N., Lawlor, D. & Brickley, E. Comparisons between countries are essential for the control of COVID-19. Int. J. Epidemiol. 49, 1059–1062 (2020).
- Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 496 in Europe. Nature 584, 257–261 (2020).
- Fernández-Villaverde, J. & Jones, C. Macroeconomic Outcomes and COVID-19: A Progress 498 Report. Working Paper 28004 (National Bureau of Economic Research, 2020).
- Saladino, V., Algeri, D. & Auriemma, V. The Psychological and Social Impact of Covid-19: 500 New Perspectives of Well-Being. Front. Psychol. 11. ISSN: 1664-1078 (2020). 501
- Villani, L., McKee, M., Cascini, F., Ricciardi, W. & Boccia, S. Comparison of Deaths Rates for COVID-19 across Europe During the First Wave of the COVID-19 Pandemic. *Front. Public Health* 8, 620416 (2020).
- Probert, W. et al. Decision-making for foot-and-mouth disease control: Objectives matter. 505 Epidemics 15, 10–19. ISSN: 1755-4365 (2016).
- Kar, T. & Jana, S. A theoretical study on mathematical modelling of an infectious disease with application of optimal control. *Biosystems* 111, 37–50. ISSN: 0303-2647 (2013).
- 13. Sharomi, O. & Malik, T. Optimal control in epidemiology. Ann. Oper. Res. 251, 55–71 (2017). 509
- Silva, C. *et al.* Optimal control of the COVID-19 pandemic: controlled sanitary deconfinement <sup>510</sup> in Portugal. *Sci. Rep.* **11**, 3451 (2021).
- Lashari, A. et al. Presentation of Malaria Epidemics Using Multiple Optimal Controls. J. Appl. 512 Math. 2012, 1–17 (2012).
- Gaff, H. & Schaefer, E. Optimal control applied to vaccination and treatment strategies for various epidemiological models. *Math. Biosci. Eng.* 6, 469–492 (2009).
- Kantner, M. & Koprucki, T. Beyond just "flattening the curve": Optimal control of epidemics 516 with purely non-pharmaceutical interventions. J. Math. Ind. 10 (2020). 517
- Thompson, R., Gilligan, C. & Cunniffe, N. Control fast or control smart: When should invading pathogens be controlled? *PLoS Comput. Bio.* 14, e1006014 (2018).
- Moore, S., Hill, E., Tildesley, M., Dyson, L. & Keeling, M. Vaccination and non-pharmaceutical <sup>520</sup> interventions for COVID-19: a mathematical modelling study. *Lancet Infect. Dis.* 21, 739–802 <sup>521</sup> (2021).

20.	Sandmann, F., Davies, N., Vassall, A., Edmunds, W. & Jit, M. The potential health and	523
	economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a trans-	524
	mission model-based future scenario analysis and economic evaluation. Lancet Infect. Dis. 21,	525
	962-974 (2021).	526

- Kaur, S. & Gupta, V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 288, 527 198114 (2020).
- Fontanet, A. & Cauchemez, S. COVID-19 herd immunity: where are we? *Nature Rev. Immunol.* 529
   20, 583–584 (2020). 530
- Keeling, M. et al. Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. Stat. Methods Med. Res. 31, 1716–1737 (2022).
- Prem, K., Cook, A. & Jit, M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. *PLoS Comput. Bio.* 13, 1–21 (2017).
- Diekmann, O., Heesterbeek, J. & Roberts, M. The construction of next-generation matrices for compartmental epidemic models. J. R. Soc. Interface 7, 873–885 (2010).
- Read, J. *et al.* Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic 537 wave. *The Lancet* **398**, 1037–1038. ISSN: 0140-6736 (2021).
- Wearing, H., Rohani, P. & Keeling, M. Appropriate Models for the Management of Infectious 539 Diseases. *PLOS Medicine* 2, e174 (2005).
- Mathieu, E. et al. A global database of COVID-19 vaccinations. Nat. Human Behav. 5, 947– 953 (2021).
- Sasanami, M., Fujimoto, M., Kayano, T., Hayashi, K. & Nishiura, H. Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination.
   *J. Theor. Biol.* 559, 111384 (2023).
- Keeling, M. & Rohani, P. Modeling infectious diseases in humans and animals (Princeton 546 University Press, 2011).
- 31. Keeling, M., Moore, S., Penman, B. & Hill, E. The impacts of SARS-CoV-2 vaccine dose 548 separation and targeting on the COVID-19 epidemic in England. *Nat. Commun.* **14** (2023). 549
- Panchal, U. et al. The impact of COVID-19 lockdown on child and adolescent mental health: 550 systematic review. Eur. Child Adolesc. Psychiatry 32, 1151–1177 (2023). 551
- Søreide, K. et al. Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services. British Journal of Surgery 107, 1250–1261 (2020).
- 34. Tildesley, M. et al. Optimal health and economic impact of non-pharmaceutical intervention 554 measures prior and post vaccination in England: a mathematical modelling study. R. Soc. 555 Open Sci. 374 (2022). 556

 Colas, C. et al. EpidemiOptim: A Toolbox for the Optimization of Control Policies in Epidemiological Models. J. Artif. Intell. Res. 71, 479–519 (2021).